Molecular Profile Detail

Profile Name KIT exon 11 del
Gene Variant Detail

KIT exon 11 del (gain of function)

Relevant Treatment Approaches KIT Inhibitor


  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"


  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Relevant Treatment Approaches Therapy Name Approval Status Evidence Type Efficacy Evidence References
KIT exon 11 del gastrointestinal stromal tumor predicted - sensitive KIT Inhibitor Imatinib Phase III Actionable In a Phase III trial, gastrointestinal stromal tumor patients harboring KIT exon 11 deletions or indels demonstrated improved improved recurrence-free survival (RFS) with 3-year adjuvant Gleevec (imatinib) treatment (5-year RFS, 70%), compared to patients receiving 1-year treatment (5-year RFS, 41.3%) (PMID: 28334365). 28334365
KIT exon 11 del gastrointestinal stromal tumor predicted - sensitive KIT Inhibitor AZD3229 Preclinical - Cell line xenograft Actionable In a preclinical study, AZD3229 inhibited Kit signaling, resulted in tumor regression in cell line xenograft models of gastrointestinal stromal tumor harboring KIT exon 11 deletion mutation (Proceedings of the American Association for Cancer Research, Vol 60, Mar 2019, Abstract #1328). detail...
Clinical Trial Phase Therapies Title Recruitment Status